Follow DRNO on...
Newly merged health data giant QuintilesIMS is collaborating with a number of global pharmaceuticals firms to develop better insights into how cancer treatments are used in a real-world setting across key European markets. More
IMS Health has allied with Beijing-based big data company Medbanks to roll out the latter's oncology-focused clinical database in China. More
The IMS Institute for Healthcare Informatics has opened a branch in Singapore, where it will build relationships in the public and private sectors, and apply analytics-driven approaches for disease modelling and insights. More
In the US, pharma data giant IMS Health and healthcare consultancy Quintiles have confirmed details of the new senior management team to be established following their planned merger. More
Pharma data giant IMS Health has acquired a Canadian company called Privacy Analytics, which provides technology solutions for de-identifying and anonymizing structured and unstructured patient-level data. Terms of the deal were not disclosed. More
IMS Health and healthcare consultancy Quintiles are planning to merge in an all-stock transaction which will value the combined company - Quintiles IMS Holdings - at $17.6 billion. Combined 2015 revenue for the two firms was around $7.2 billion. More
Holding company Symphony Technology Group (STG) has sold its biopharma and consumer health research and analytics firm AlphaImpactRx to IMS Health. Terms of the deal were not disclosed. More
Pharma data giant IMS Health has launched an app that delivers the company's materials from nineteen countries directly to Apple and Android tablets. More
Pharma research giant IMS Health has reported second quarter revenue up 5.2% on a like-for-like basis, allowing for currency changes and the acquisition of assets of Cegedim. Reported revenue was up 12.0% to $742m, equivalent to a 24.6% rise at constant currency. More
US-based healthcare data giant IMS Health has closed its secondary public offering of approximately 58 million shares of common stock by existing shareholders, at a price to the public of $27.50 per share. More
Pharma data giant IMS Health has acquired healthcare big data analytics specialist Dataline Software. Terms of the deal were not disclosed. More
Pharma data giant IMS Health has announced results for the quarter ended March 31st, with revenue up 7.0% at constant currency, to $632m and profit also jumping - adjusted EBITDA was $216n, up 9.8% at constant currency. More
Pharma research and data giant IMS Health has announced results for the quarter and year ended December 31st 2014, including revenue up 6.2% to $678m in Q4 and 5.9% to $2,641m for the full year on a constant currency basis; and adjusted EBITDA up 8.5% and 9.5% respectively. More
Pharma research and data giant IMS Health has announced results for the quarter ended September 30th, with revenue up 5.4% (constant currencies) to $656m, driven by a strong performance in technology services (up 10.8%). Profits were also healthy - adjusted EBITDA increased 10.5% to $221m. More
In the US, pharma research giant IMS Health has unveiled a cloud-based sales performance solution called Nexxus Mobile Sales. The product combines continuously updated industry and customer data with expert decision support tools for sales reps. More
Pharma research giant IMS Health has reported a 6.1% increase in second quarter revenue to $662m. However, due to a number of one-off charges and expenses the firm suffered a Q2 net loss of $200m, compared with net income of $8m in the prior year period. More
In the US, pharm data giant IMS Health has announced its intention to acquire information solutions and CRM businesses from Cegedim, for around EUR 385m ($520m) in cash. More
IMS Health has acquired Belgian-based business intelligence tech company Forcea, with the aim of enhancing its performance management capabilities for hospitals and life sciences clients. Terms were not disclosed. More
IMS Health has proceeded with its IPO, raising $1.3bn, and shares have risen by 15 percent on its trading debut. More
Pharma research giant IMS Health is preparing to launch an Initial Public Offering (IPO) in the next fortnight, which could value the company at around $7 billion. More
Pharma research giant IMS Health Holdings has filed a registration with the US Securities and Exchange Commission (SEC) for an Initial Public Offering (IPO) on the New York Stock Exchange. More
IMS Health has acquired Swedish life sciences advisory and analytics firm Pygargus for an undisclosed sum. More
IMS Health has partnered with the Life Sciences division of BroadReach Healthcare, to offer advisory services, commercial solutions and market measurement for life sciences clients operating in Africa. More
IMS Health is to acquire the assets of Toronto-based Diversinet, including intellectual property, software and customer contracts, for around $US 3.5m. More
Pharma data giant IMS Health has acquired SaaS firm Incential Software, as it looks to extend its performance management capabilities for life sciences organizations worldwide. Terms of the deal were not disclosed. More
Pharma data giant IMS Health has announced the acquisition of US marketing technology provider 360 Vantage, with an eye to extending its commercial Software-as-a-Service offer for life sciences and healthcare clients. More
In the US, IMS Health and Remedy Informatics have partnered to deliver technology-based 'real-world-evidence' (RWE) solutions, promising life science sector clients a complete picture of the patient experience. More
US research giant IMS Health has acquired social media analytics firm Semantelli for an undisclosed sum. More
Healthcare research giant IMS Health has acquired Seattle-based technology firm Appature, which offers clients a patented cloud-based marketing software platform called Nexus. Terms of the deal were not disclosed. More
Healthcare research and information giant IMS Health is to consolidate a number of its San Francisco offices into one site, and has reportedly leased the entire seventh floor of the 38-story block at 425 Market St. from May onwards. More
Healthcare research giant IMS Health is to integrate Health Intelligence Company's (HIC) health plan claims database into its IMS LifeLink portfolio of tools, which provide a view of treatment decisions for more than 210 million patients in the US. More
US-based research giant IMS Health has acquired PharmaDeals, which provides online information about business transactions, licensing, and mergers and acquisition activity across the global pharmaceutical industry. Terms were not disclosed. More
US-based research giant IMS Health has acquired benchmarking solutions and analytics company TTC, which helps life science firms plan for and negotiate the costs of clinical trials. Terms of the deal were not disclosed. More
In the US, IMS Health has acquired San Francisco-based software firm DecisionView, which helps life sciences organizations plan and track patient enrollment for clinical trials around the world. Terms of the deal were not disclosed. More
In the US, the FTC has approved inVentiv Health's acquisition of two SDI Health promotional and medical audit businesses from IMS Health; while separately, inVentiv is to acquire outsourcing solutions firm Kforce Clinical Research. More
Pharma market research giant IMS Health has acquired Bangalore-based PharmARC, which specializes in analytics and other services for the life sciences industry. Terms of the deal were not disclosed. More
IMS Health has found a home for two of SDI's product lines, after the Federal Trade Commission determined they must be sold for competition reasons following IMS' acquisition of SDI. US healthcare consultancy inVentiv has acquired the businesses for an undisclosed sum. More
Raymond Hill has stepped down from his role as CEO of contract drug research organization PPD Inc with a $3.065m payment, just three months after leaving his previous position at pharma market research giant IMS Health. More
In the US, the Federal Trade Commission says the parent company of IMS Health must sell two product lines if it is to proceed with its acquisition of rival data provider SDI. More
In the US, the Supreme Court has overturned a Vermont law which banned the use of physician prescription information for marketing purposes. The reform had been driven by IMS Health, SDI, Source Healthcare Analytics and a US pharma research association. More
In the US, Attorney General William Sorrell has filed a petition with the Supreme Court to review a decision previously made by a court in Vermont, which allows the collection and use of prescriber-identifiable data for marketing or promoting prescription drugs. More
Pharma market research giant IMS Health has appointed Ari Bousbib as its new Chief Executive Officer, replacing David Carlucci who will continue to serve in his other role as Chairman for a transition period. More
Pharma market research giant IMS Health has expanded its IMS Oncology Analyzer market measurement tool to provide anonymized patient-level information across several additional cities in China. More
In the US, health care research giant IMS Health has announced completion of its acquisition by investment firms TPG Capital and the Canada Pension Plan Investment Board (CPPIB), for $5.2bn. More
Pharma market research giant IMS Health has launched a set of solutions to help clients comply with US federal and state transparency and marketing disclosure laws covering what is known as 'aggregate spend'. More
US research giant IMS Health has reported a 3% increase in fourth quarter revenues to $599.2m. The firm has also received shareholder approval for its sale to TPG Capital and the CPP Investment Board. More
Pharmaceutical research giant IMS Health has received clearance from the European Commission (EC) to proceed with its sale to US investment firms TPG Capital and Canada Pension Plan Investment Board (CPPIB) for $5.2bn. More
Healthcare intelligence provider IMS Health is planning to launch an analytical tool that enables firms to assess treatment opportunities and guide commercial decisions in the $48bn global oncology market. More
Pharmaceutical research giant IMS Health has agreed to be sold to private equity firm TPG Capital and the Canada Pension Plan Investment Board (CPPIB) for $5.2bn. More
Pharma market research giant IMS Health has reported a 6% drop in third-quarter revenue to $540.8m, compared with $573.7m a year earlier. The news follows reports earlier in the week that the Board of Directors is considering selling the company. More
According to reports, pharma market research giant IMS Health is in talks with several private equity firms regarding selling the company. More
IMS Health has launched a new tool that provides an understanding at both the molecule and product level of market size, performance and changing biologics usage in more than 70 countries. More
Pharma market research giant IMS Health has appointed Gilles Pajot in the new position of Vice Chairman. Previously the company's COO, he continues to report to Chairman and CEO David R. Carlucci. More
Pharma market research giant IMS Health has launched a web-based Q&A service to provide healthcare industry market intelligence and insights to newly-founded biopharmaceutical companies. More
Pharma market research giant IMS Health has launched a web-based tool which it claims provides an alternative to custom primary market research for assessing brand promotional campaigns. More
Pharma market research giant IMS Health has reported a 19% drop in Q2 profit to $62.9m from $77.7m a year earlier. Accordingly, the firm is planning to shed a total of 850 staff, or 11% of its global workforce. More
Robert Louis-Dreyfus, former CEO of pharma MR giant IMS Health and the main shareholder in French soccer team Olympique Marseille, has died at the age of 63 after a long battle with leukaemia. More
US healthcare market intelligence provider IMS Health has appointed Kimberly Gray as Chief Privacy Officer for the Americas, to direct all privacy-related activities for the US, Canada and Latin America. More
In the US, the Supreme Court says it will not consider overturning a New Hampshire ban on the use of prescriber-identifiable data for marketing purposes. The law is contested by research and data firms including IMS Health and SDI / Verispan. More
US research trade bodies CASRO and PMRG have given their support to health care MR specialists IMS Health, Inc. and Verispan LLC in their attempt to overturn a Court of Appeals ruling which would prevent them from using prescriber-identifiable data for marketing purposes. More
US pharma research giant IMS Health has seen total first quarter revenue fall 8% to $526.9m from $574.2m as the strong dollar impacts on overseas sales. Nevertheless, the quarter saw a sharp rise in net income. More
IMS Health and SDI have petitioned the US Supreme Court to review a Court of Appeals ruling which would prevent them from using prescriber-identifiable data. More
Pharmaceutical research giant IMS Health has reported third-quarter revenue of $574m, up 6%, or a modest 3% year-on-year on a constant dollar basis. However, net income and EPS grew 33% and 41% respectively in the quarter. More
Pharmaceutical research leader IMS Health has confirmed the acquisition of Russian research and analytics firm RMBC, first announced in January. More
IMS Health has announced second-quarter revenue up 12% (4% at constant currencies) to $600.7m. Operating income rose 11% (1% at constant currencies) to $131.4m. Net income on a GAAP basis was $77.7m, compared with $73.4m in the year-earlier quarter, an increase of 6%. More
In the US, pharma research giant IMS Health has joined with ten academic researchers to establish the Health Services Research Network (HSRN), to conduct detailed, national-level studies of key health services and their outcomes. More
In the US, IMS Health has finished quarter one with 13% revenue growth to $574m, on the back of its 'aggressive' restructuring actions. More
In British Columbia, Canada, new legislation has been passed which according to Health Minister George Abbott, prohibits disclosure of information from electronic databases for market research and allows individuals access to their own health records and medical information. More
Pharma research leader IMS Health has announced full year 2007 revenues up 12% (a very respectable 8% at constant currency) to $2,192.6m. Operating income for the year was down from $444.2m to $393.3m after a fourth quarter restructuring charge of $88.7m. More
Pharma research specialist IMS Health will conclude a deal at the end of the month to buy Russian competitor RMBC for an estimated cost of between $4.5m and $7m. The acquisition will increase IMS' share of the Russian pharma research market from 10% to approximately 40%. More
Global pharma research firm IMS Health has announced plans to cut staff numbers by 10% during 2008 in an effort to save money and improve efficiency. More
The U.S. District Court for the District of Maine has granted the preliminary injunction sought by three research and information firms to block enforcement of Maine's Prescription Restraint Law, LD-4. More
Pharmaceutical and healthcare research giant IMS Health has acquired analytics and technology firm MIHS Holdings, Inc, which has two subsidiaries – IHS and MedInitiatives. More
In the US, pharma research firm IMS Health has reported poor third-quarter earnings and reduced its 2007 profit outlook – initially sending shares plummeting 22% to $22.99. More
In the US, IMS Health, Wolters Kluwer Health (through its subsidiary Source Healthcare Analytics) and Verispan have filed suits against the states of Maine and Vermont to prevent the passing of laws restricting the collection and disclosure of physician prescribing information. More
IMS Health has named Kevin Knightly in the new role of Senior VP, Business Line Management, and promoted Adel Al-Saleh to replace him as President, Europe, Middle East and Africa (EMEA). More
Pharmaceutical and healthcare intelligence giant IMS Health continues its recent growth, today announcing second-quarter revenue up 11% on the year (8% at constant currencies) to $537.5m. More
Shares in pharma MR leader IMS Health have risen to an eight-year high after a US federal judge overturned a New Hampshire state law banning the commercial use of physician prescription pattern data. More
Arbitron, Confirmit and IMS Health have all reported buoyant first quarters, with revenues up 7.9%, 14% and 35% respectively. More
IMS Health has acquired ValueMedics Research LLC, significantly extending its Healthcare Economics and Outcomes Research (HEOR) expertise in the US as well as its global capabilities. More
IMS Health has announced the full deployment of 'Next-Generation Prescription Services(TM)', a large-scale enhancement to its core prescription offerings in the US. Improvements include more timely delivery and better coverage of prescriptions by specialists. More
Pharma and healthcare research giant IMS Health has promoted Gilles Pajot to COO and Leslye Katz as Senior VP and CFO. The firm has also been in a federal court this week, defending the right of companies to see prescription data from individual physicians. More
Research giant IMS Health has announced the election to its board of directors of Bret W. Wise, President and CEO of Dentsply International, Inc. The company has also unveiled plans to repurchase another ten million of its shares. More
IMS Health is to buy the Life Sciences practice of US-based Strategic Decisions Group (SDG), which focuses on portfolio strategy consulting for the pharmaceutical and biotech industries. More
Pharma research giant IMS Health has announced it has successfully integrated anonymised patient-level data (APLD) across its global portfolio of information, analytics and consulting; and established a new global team of health economics and outcomes experts. More
Healthcare and pharma information giant IMS Health has announced a comprehensive global program – 'New Models, New Metrics' – to provide the industry's 'next generation of market measurement services'. The program's first launch is 'MIDAS Market Segmentation(TM)'. More
IMS Health has announced a multi-year alliance with oncology information provider IntrinsiQ Research. IMS gains an exclusive license to incorporate IntrinsiQ's US-based anonymized patient-level information with its own IMS Oncology Analyzer(TM) to create one of the largest oncology information sources. More
For a change, a major firm's Chief Financial Officer has resigned just after the publication of some *good* results. IMS Health has announced that Nancy E. Cooper will leave the company following a brief transition period, to join CA, an IT management software company. More
IMS Health has announced second-quarter 2006 revenue of US$486.2 million, up 12% on a reported and constant-dollar basis, on the year earlier period. The company also announced that it is raising its 2006 earnings-per-share guidance. More
TNS Healthcare has appointed Paula Paradise as Vice President, Business Development. She worked at IMS Health in many senior positions in addition to spells at Elan, Wood MacKenzie and recently IMPACTRx. More
Pharmaceutical information giant IMS Health has announced a strong start to the year reporting first-quarter 2006 revenues of US$446.2 million, up 9% on the previous year. More
IMS Health has named David R. Carlucci as its Chairman, effective from April 1, in addition to his existing roles as CEO and President. Carlucci, 51, succeeds David M. Thomas, 56, who is retiring from the IMS Health Board of Directors at the same time. More
A group of VNU shareholders is pressing the Dutch company to break itself into three divisions and sell each separately rather than agree to the proposed 7.3bn Euro buyout deal with private-equity firms, according to reports today in the Wall Street Journal. More
IMS Health has reported a successful 2005, with revenues increasing by 12% and earnings per share 17% higher than in 2004. The company has also announced a $750m share repurchase, and plans to increase the annual dividend by 50%. More
IMS Health has appointed Gilles Pajot to the new position of President, Global Business Management. Pajot was previously President for Europe, Middle East and Africa (EMEA) - a role now taken by Kevin Knightly, formerly Chief Financial Officer for North America and Europe. More
After weeks of speculation, VNU revealed today that it a private equity consortium has offered to buy the company for 28 to 28.5 Euros per common share. VNU says it is considering the proposal, and is not proceeding with discussions with any other party. More
VNU, owner of ACNielsen and Nielsen Media Research, is to give potential private equity bidders limited access to its books, according to reports in the Financial Times last week. Shares in the company rose by more than 4% following the FT report. More
PharMetrics, a unit of IMS Health, has launched a new Cost of Care market intelligence module to measure and assess the value of pharmaceutical products. The service, which incorporates insights from patients, is designed to help pharma marketers create more value-oriented messages. More
Shares in VNU, owner of ACNielsen and Nielsen Media Research, rose more than 4% on Friday after reports that two private equity firms were considering making bids for the Netherlands-based company. More
VNU's CEO Rob van den Bergh is stepping down, following the announcement that the company's planned takeover of IMS Health has been terminated due to strong resistance from VNU shareholders. Under the termination agreement, VNU will reimburse IMS $15 million for out-of-pocket costs. More
IMS Health is launching a new range of tools for pharmaceutical marketers. The products - known as IMS Promo.360 - make use of industry benchmarks to measure promotion effectiveness and brand perception. More
VNU has announced that its plan to take over IMS Health may be about to collapse. The company says it is in 'wide-ranging discussions' with IMS Health over possible alternatives to the proposed merger. One of the possible alternatives is an end to the $7 billion acquisition plan. More
The US Pharmaceutical Institute has launched its own Research Center, offering custom research services to the industry. Meanwhile, IMS Health predicts that the international pharma market will grow by 6 to 7% in 2006, driven by above-average US growth and double-digit increases in China and Eastern Europe. More
IMS Health has announced third-quarter 2005 revenues of $432.8 million, up 13% from the third quarter of 2004. Meanwhile, reports suggest that the proposed $7bn takeover of the company by VNU may be scrapped due to opposition by VNU shareholders. More
IMS Health has established a global partnership with business intelligence software and services company SAS, to develop leading-edge market intelligence solutions for the pharma and healthcare industry. The first result, IMS Sales Force Effectiveness Precision Suite, is launched this week. More
IMS Health, which recently announced its merger with VNU, has reported positive financial results for the second quarter of this year. Revenues were up 14% from the same time last year, with the US and Europe reporting the strongest growth. More
The MR landscape is to undergo a seismic shift as VNU, the world's biggest research provider, buys IMS Health, the next biggest in the US, in a transaction valued at 5.8 billion Euros ($7.0 billion). VNU's CEO is confident that the deal will quickly lead to major cost savings and new revenues. More
IMS Health has announced a definitive agreement to acquire business intelligence provider PharMetrics, Inc., specialist in patient-centric integrated claims data. The terms were not disclosed. More
US prescription drug sales grew 8.3% from $217.3bn in 2003 to $235.4bn last year, according to IMS Health. The volume of total US dispensed prescriptions grew 3.2% after adjustments. Despite seeing less than double-digit growth for the first year since 1995, the industry's performance is seen as solid in the face of various pressures. More
IMS Health has named David R. Carlucci, currently President and COO, as its new CEO from January 1, 2005. He succeeds David M. Thomas, who remains Executive Chairman of the board of directors and will focus on long-term growth strategy and new business development. More
Pharmaceutical MR giant IMS Health, which last week announced positive second quarter results, is to acquire United Research China (URC) Shanghai, which offers OTC and Consumer Health survey services including syndicated research. More
IMS Health and Premier Healthcare Informatics have announced an exclusive co-marketing agreement for a new information service, IMS Inpatient Therapy Profiler. The service provide insights into hospital drug and medical device utilization and disease treatment. More
Last week, a U.S. District Court judge set a trial date of September 20, 2004 in Information Resources, Inc.'s antitrust lawsuit against ACNielsen (now owned by VNU), The Dun & Bradstreet Corp., and IMS International, in which IRI is seeking damages in excess of $1 billion after trebling. The jury trial in this case is scheduled to last between ten and sixteen weeks. More
Last week the US District Court for the Southern District of New York issued two key rulings for Information Resources, Inc. in its $350 million-plus antitrust lawsuit against Dun & Bradstreet, ACNielsen and IMS International. More
IMS Health has recently announced a three-year agreement to provide Pfizer Inc. with data, analytics and advisory services. The collaboration is part of a comprehensive programme covering 23 countries that aims to enhance Pfizer's effectiveness in informing physicians about its innovative medicines. More
The US business unit of IMS Health has acquired New Hampshire-based Marketing Initiatives, Inc. (MII), an information and services firm specialising in healthcare facility profile data. More
IMS Health has reported diluted earnings per share from recurring operations of $0.27 for the quarter ended September 30, 2002, equal to last year's third quarter and consistent with previous expectations. More
IMS Health has reported diluted earnings per share from recurring operations of $0.23 for the quarter ended June 30, 2002, up 5 percent from last year's second quarter. Net income from recurring operations was $66.0 million, essentially unchanged year over year. More
Healthcare researcher IMS has recently announced the launch of a new web-based aid to pharmaceutical marketing. Christened as the 'IMS Marketing Effectiveness Suite' of applications, the package should help professionals to address a raft of lifecycle questions for their medical products. More
IMS HEALTH has announced full-year 2001 diluted earnings per share of $0.90 from recurring operations, a 6% increase over 2000 results. Net income from recurring operations grew 7% year over year, to $270.6 million. More
At the end of last year, Martin Hamblin GfK acquired several PMSI services based at High Wycombe in the UK from IMS HEALTH. More
IMS HEALTH expects financial results for the 2001 fourth quarter to be below analysts' expectations, with core revenue ranging from US$295 million to US$305 million, or a range of negative 2 percent to positive 2 percent constant dollar growth, and earnings per share of $0.22 - $0.23, a decline of between 12% to 15% from the 2000 fourth quarter. More
IMS Health has acquired Cambridge Pharma, a privately held international consulting and advisory firm providing services tailored to the pharmaceutical and healthcare industries. The transaction details have not been disclosed. More
Register (free) for Daily Research News
REGISTER FOR NEWS EMAILS
To receive (free) news headlines by email, please register online
